Journal of Basic Research in Medical Sciences
Volume 9, Issue 4 (9-2022)
jbrms 2022, 9(4): 1-11 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Maddahi S Z, Jokar A, Behnampur N, Kamalinejad M, Fakhri M. Effects of Ziziphus jujuba on the Prevention of Drug Induced Liver Enzyme Disorders in Pulmonary Tuberculosis Patients: Protocol for Randomized controlled trial. jbrms 2022; 9 (4) :1-11
URL: http://jbrms.medilam.ac.ir/article-1-644-en.html
URL: http://jbrms.medilam.ac.ir/article-1-644-en.html
Department of Biostatistics, Health Management and Social Development Research Center, Golestan University of Medical Sciences, Gorgan, Iran
Abstract: (1461 Views)
Liver damage is the most common complication of anti-tuberculosis drugs, but there is currently no standard prevention for it. The main purpose of this study is to determine the effectiveness of Ziziphus jujuba (Z. jujuba) syrup on the prevention of liver enzyme disorder in TB patients.
This study is a protocol for randomized controlled trial. 48 patients will be included in the study who will be randomly assigned to one of the two groups of Z. jujuba syrup or placebo syrup based on the block randomization. Liver enzyme tests are measured at the beginning of the study, as well as days 14 and 28 of the study, which will be the primary outcome. The standard Visual Analog Scales questionnaire will be completed on days 0, 14, and 28 to assess cough, anorexia, and nausea in patients. The standard SF-36 quality of life questionnaire will be completed on days 0 and 28 of the study, which will be evaluated as the secondary outcome of the study.
The hypothesis of the study is that the incidence rate of liver enzyme disorder will be lower in patients treated with Z. jujuba, compared to those who received the placebo.
This study is a protocol for randomized controlled trial. 48 patients will be included in the study who will be randomly assigned to one of the two groups of Z. jujuba syrup or placebo syrup based on the block randomization. Liver enzyme tests are measured at the beginning of the study, as well as days 14 and 28 of the study, which will be the primary outcome. The standard Visual Analog Scales questionnaire will be completed on days 0, 14, and 28 to assess cough, anorexia, and nausea in patients. The standard SF-36 quality of life questionnaire will be completed on days 0 and 28 of the study, which will be evaluated as the secondary outcome of the study.
The hypothesis of the study is that the incidence rate of liver enzyme disorder will be lower in patients treated with Z. jujuba, compared to those who received the placebo.
Type of Study: Review Article |
Subject:
Pharmacology
Received: 2021/12/8 | Accepted: 2022/08/20 | Published: 2023/02/16
Received: 2021/12/8 | Accepted: 2022/08/20 | Published: 2023/02/16
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |